Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Boehringer Ingelheim
McKinsey
Mallinckrodt
Dow

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,723,593

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 5,723,593
Title: Diagnostic assay for Charcot Marie Tooth Disease Type 1B
Abstract:The present invention provides compositions, methods and kits for the detection of genetic polymorphisms or mutations related to Charcot-Marie-Tooth Disease Type 1B. The polymorphism or mutations generally occur in the protein P0 gene in chromosome 1. Also provided are mutant forms of protein P0 and methods for screening compounds to identify compounds that enhance binding between mutant P0 proteins.
Inventor(s): Lebo; Roger V. (San Francisco, CA), Ravetch; Jeffrey V. (New York, NY)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:08/485,479
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,723,593
Patent Claims:1. A composition for detection of a gene associated with Charcot-Marie-Tooth Disease Type 1B comprised of two amplification primers, wherein the first amplification primer is to

TTC CAC TAT GCC AAG GGA CAA C; (SEQ ID NO:1),

and the second amplification primer is to

CTG GTG GGT TTT TGA CAT CAC AT (SEQ ID NO:2).

2. A kit for the detection of genetic polymorphisms associated with Charcot-Marie-Tooth Disease Type 1B, comprising a vial containing SEQ ID NO:1 and SEQ ID NO:2.

3. A kit as in claim 2, further comprising a vial containing a thermostable polymerase.

4. A composition for the detection of a gene associated with Charcot-Marie-Tooth Disease Type B, comprising a first oligonucleotide which binds substantially to the first intron located upstream of human myelin protein zero (P0) gene exon 2, and a second oligonucleotide which binds substantially to the second intron located downstream of human protein zero (P0) gene exon 2.

5. A composition for the detection of a gene associated with Charcot-Marie-Tooth Disease Type B, comprising a first oligonucleotide which binds substantially to the intron located upstream of human myelin protein zero (P0) gene exon 3, and a second oligonucleotide which binds substantially to the intron located downstream of human protein zero (P0) gene exon 3.

6. A composition for the detection of a gene associated with Charcot-Marie-Tooth Disease Type B, comprising a first oligonucleotide which binds substantially to the intron located upstream of human myelin protein zero (P0) gene exon 4, and a second oligonucleotide which binds substantially to the intron located downstream of human protein zero (P0) gene exon 4.

7. A composition for the detection of a gene associated with Charcot-Marie-Tooth Disease Type B, comprising a first oligonucleotide which binds substantially to the intron located upstream of human myelin protein zero (P0) gene exon 5, and a second oligonucleotide which binds substantially to the intron located downstream of human protein zero (P0) gene exon 5.

8. A composition for the detection of a gene associated with Charcot-Marie-Tooth Disease Type B, comprising a first oligonucleotide which binds substantially to the intron located upstream of human myelin protein zero (P0) gene exon 6, and a second oligonucleotide which binds substantially to the intron located downstream of human protein zero (P0) gene exon 6.

9. A method for detecting the presence of a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 1B in a sample of patient nucleic acid, comprising:

contacting the sample with an oligonucleotide which binds specifically to a nucleic acid subsequence of a human myelin protein zero (P0) gene, and

detecting hybridization of the oligonucleotide to the human myelin protein zero (P0) gene subsequence;

whereby detecting hybridization of the oligonucleotide provides a determination that the sample contains a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 1B.

10. A method as in claim 9, wherein the sample of patient nucleic acid comprises chromosomal DNA.

11. A method as in claim 10, wherein the chromosomal DNA is chromosome 1.

12. A method as in claim 9, wherein the subsequence is in an exon.

13. A method as in claim 12, wherein the exon is selected from the group consisting of human myelin protein zero (P0) gene exon 1, exon 2, exon 3, exon 4, exon 5, and exon 6.

14. A method as in claim 9, further comprising digesting the nucleic acid with a restriction enzyme to produce restriction fragments.

15. A method as in claim 14, wherein the restriction enzyme is selected from the group consisting of BstBI, ScrFI, HhaI, AluI, and EcoRII.

16. A method as in claim 14, further comprising separating the restriction fragments by gel electrophoresis.

17. A method as in claim 16, wherein the Charcot-Marie-Tooth Disease Type 1B polymorphism is identified by the migration pattern of the restriction fragments on the gel.

18. A method as in claim 16, wherein the gel electrophoresis is polyacrylamide gel electrophoresis.

19. A method as in claim 9, wherein the step of detecting hybridization of the oligonucleotide comprises amplifying the human myelin protein zero (P0) gene subsequence.

20. A method as in claim 9, wherein the subsequence is in a human myelin protein (P0) gene intron.

21. A method for detecting the presence of a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 1B in a sample of patient nucleic acid, comprising:

digesting the sample with a restriction enzyme to produce restriction fragments,

separating the restriction fragments,

contacting the fragments with an oligonucleotide that hybridizes to a nucleic acid subsequence of a human myelin protein zero (P0) gene, and

detecting hybridization of the oligonucleotide to the human myelin protein zero (P0) gene subsequence;

whereby detecting hybridization of the oligonucleotide provides a determination that the sample contains a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 1B.

22. A method as in claim 21, wherein the restriction enzyme is selected from the group consisting of BstBI, ScrFI, HhaI, AluI, and EcoRII.

23. A method as in claim 21, wherein the subsequence is in an exon.

24. A method as in claim 23, wherein the exon is selected from the group consisting of human myelin protein zero (P0) gene exon 1, exon 2, exon 3, exon 4, exon 5, and exon 6.

Details for Patent 5,723,593

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2015-03-03 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2015-03-03 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Regents of the University of California (Oakland, CA) 2015-03-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKesson
AstraZeneca
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.